Human monoclonal antibody99mTc-88BV59: Detection of colorectal cancer, recurrent or metastatic disease and immunogenicity assessment

This study presents immunoscintigraphic results in 24 patients suffering from primary colorectal cancer, recurrent or metastatic disease after the injection of 1197–1351 MBq technetium-99m labelled totally human monoclonal antibody 88BV59. Labelling efficacy of^99mTc-88BV59 ranged from 97% to 99%. Immunoscintigraphy was performed 18–20 h after injection. Scintigraphic findings were compared with those of computed tomography (CT). Patients underwent surgery in order to evaluate immunoscintigraphic findings histologically. Sera of the patients (before injection and 1 and 3 months post infusion) were analysed for the presence of human anti-human antibodies (HAHA). None of the patients showed a HAHA response as assessed by a solid-phase ELISA assay. The antibody scan detected about 25% more lesions than CT. In the detection of extrahepatic disease, the sensitivity of the antibody scan proved to be 68%, whereas the sensitivity of CT was 41%.